Commissioned by the National Medical Security Administration, the National Medical Security Administration's Pharmaceutical Price and Bidding and Procurement Guidance Center has compiled the status of pharmaceutical companies rated as “particularly seriously untrustworthy” and “seriously untrustworthy” in each province as of July 1, 2026. The announcement is as follows. Since the third quarter of 2025, the loss of trust rating has been assessed according to the 2025 discretionary benchmark and divided into “particularly serious loss of trust” and “serious loss of trust”. Previously, “particularly serious” and “serious” according to the 2020 edition, it will continue to be announced during the validity period of its loss of trust rating until the original loss of trust rating is cleared to zero.

Commissioned by the National Medical Security Administration, the National Medical Security Administration's Pharmaceutical Price and Bidding and Procurement Guidance Center has compiled the status of pharmaceutical companies rated as “particularly seriously untrustworthy” and “seriously untrustworthy” in each province as of July 1, 2026. The announcement is as follows. Since the third quarter of 2025, the loss of trust rating has been assessed according to the 2025 discretionary benchmark and divided into “particularly serious loss of trust” and “serious loss of trust”. Previously, “particularly serious” and “serious” according to the 2020 edition, it will continue to be announced during the validity period of its loss of trust rating until the original loss of trust rating is cleared to zero.